A family cluster of cutaneous Leishmania major infection unresponsive to intralesional meglumine antimonial: Case reports

Alvar, 2012, Leishmaniasis worldwide and global estimates of its incidence, PLoS One, 7, 10.1371/journal.pone.0035671 Ghatee, 2020, The geographical distribution of cutaneous leishmaniasis causative agents in Iran and its neighboring countries, A review, Front Public Health, 8, 11, 10.3389/fpubh.2020.00011 Mahmoudzadeh-Niknam, 2012, Molecular epidemiology of cutaneous leishmaniasis and heterogeneity of Leishmania major strains in Iran, Trop Med Int Health, 17, 1335, 10.1111/j.1365-3156.2012.03078.x Asilian, 1995, A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran, Am J Trop Med Hyg, 53, 648, 10.4269/ajtmh.1995.53.648 Solomon, 2016, Unusual forms of cutaneous leishmaniasis due to Leishmania major, J Eur Acad Dermatol Venereol, 30, 1171, 10.1111/jdv.13220 Munir, 2008, Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis, Acta Dermatovenerol Croat, 16, 60 Monge-Maillo, 2013, Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis, Drugs, 73, 1889, 10.1007/s40265-013-0132-1 Pourmohammadi, 2019, Molecular detection of Leishmania major in Hemiechinus auritus: a potential reservoir of zoonotic cutaneous leishmaniasis in Damghan, Iran, J Arthropod Borne Dis, 13, 334 Schönian, 2003, PCR diagnosis and characterization of Leishmania in local and imported clinical samples, Diagn Microbiol Infect Dis, 47, 349, 10.1016/S0732-8893(03)00093-2 Harrison, 2017, Progressive perforation of the nasal septum due to Leishmania major: a case of mucosal leishmaniasis in a traveler, Am J Trop Med Hyg, 96, 653 Galvao, 2017, Efficacy of azole therapy for tegumentary leishmaniasis: a systematic review and meta-analysis, PLoS One, 12, 10.1371/journal.pone.0186117 Salmanpour, 2001, Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis, J Dermatol Treat, 12, 159, 10.1080/09546630152607899 Alsaleh, 1995, Ketoconazole in the treatment of cutaneous leishmaniasis in Kuwait, Int J Dermatol, 34, 495, 10.1111/j.1365-4362.1995.tb00622.x Ozgoztasi, 1997, A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey, Int J Dermatol, 36, 61, 10.1046/j.1365-4362.1997.00022.x Singh, 1995, Failure of ketoconazole treatment in cutaneous leishmaniasis, Int J Dermatol, 34, 120, 10.1111/j.1365-4362.1995.tb03595.x Navin, 1992, Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala, J Infect Dis, 165, 528, 10.1093/infdis/165.3.528 Lake-Bakaar, 1987, Hepatic reactions associated with ketoconazole in the United Kingdom, Br Med J, 294, 419, 10.1136/bmj.294.6569.419 de Oliveira Duque, 2019, Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit, Acta Trop, 193, 176, 10.1016/j.actatropica.2019.03.007 Al-Salem, 2019, Old world cutaneous leishmaniasis treatment response varies depending on parasite species, geographical location and development of secondary infection, Parasites Vectors, 12, 195, 10.1186/s13071-019-3453-4 Myint, 2008, Polymorphisms of cytochrome b gene in Leishmania parasites and their relation to types of cutaneous leishmaniasis lesions in Pakistan, J Dermatol, 35, 76, 10.1111/j.1346-8138.2008.00419.x Zheng, 2020, Integrative genomic, proteomic and phenotypic studies of Leishmania donovani strains revealed genetic features associated with virulence and antimony-resistance, Parasites Vectors, 13, 510, 10.1186/s13071-020-04397-4 Al-Gindan, 1983, A case of mucocutaneous leishmaniasis in Saudi Arabia caused by Leishmania major and its response to treatment, Clin Exp Dermatol, 8, 185, 10.1111/j.1365-2230.1983.tb01763.x Shirian, 2013, Three Leishmania/L. species–L. infantum, L. major, L. tropica–as causative agents of mucosal leishmaniasis in Iran, Pathog Glob Health, 107, 267, 10.1179/2047773213Y.0000000098 Aruleba, 2020, Can we harness immune responses to improve drug treatment in leishmaniasis?, Microorganisms, 8, 1069, 10.3390/microorganisms8071069 Boggild, 2019, Cutaneous and mucocutaneous leishmaniasis in travellers and migrants: a 20-year GeoSentinel Surveillance Network analysis, J Trav Med, 26, taz055, 10.1093/jtm/taz055 dos Santos Meira, 2019, Protective or detrimental? Understanding the role of host immunity in leishmaniasis, Microorganisms, 7, 695, 10.3390/microorganisms7120695 Scott, 2016, Cutaneous leishmaniasis: immune responses in protection and pathogenesis, Nat Rev Immunol, 16, 581, 10.1038/nri.2016.72 Carvalho, 1995, Characterization of the immune response in subjects with self-healing cutaneous leishmaniasis, Am J Trop Med Hyg, 53, 273, 10.4269/ajtmh.1995.53.273 Weinstock, 1997, Impaired production of cytokines in a case of human leishmaniasis, Clin Infect Dis, 25, 1334, 10.1086/516123